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Each year, approximately 400,000 commercial 
motor vehicle (CMV) accidents occur on U.S 
roadways. Truck accidents represent a 
significant portion of these accidents, as they 
account for approximately 12 percent of all 
traffic accident fatalities (USDOT, Federal 
Motor Carrier Safety Administration, 2013). The 
prevention of accidents involving CMVs is a 
large public safety concern, since: (1) CMV 
drivers are licensed to operate commercial 
passenger vehicles and vehicles that may contain 
hazardous chemicals, and (2) there is a much 
higher fatality risk for individuals in vehicles 
that are accidentally struck by larger CMVs 
(National Highway Traffic Safety 
Administration, 2002). Within the public safety 
concern of CMV accidents exists a public health 
concern- the health of CMV truck drivers. Truck 
drivers are known to have higher rates of 
obstructive sleep apnea (OSA) compared to the 
general population. This condition is related to 
other health-related morbidities, as well as 
fatigue that can result in traffic accidents.  
 
Recognizing the seriousness of OSA prevalence 
among CMV drivers, the Federal Motor Carrier 
Safety Administration (FMCSA) itself initiated 
a bill that unanimously passed the U.S. Senate. 
The bill requires the formal rule-making process 
to be followed regarding OSA screening, testing, 
and treatment of CMV drivers. It forbids the 
issuing of any informal guidance on this subject 
outside of the regulatory, rule-making process 
(GPO, 2013). Although the bill does not require 
the FMCSA to conduct mandatory screening, it 
allows for various experts to provide valuable 
data and input for the United States Department 
of Transportation (USDOT) to consider in 
developing its regulations. A formal rule-making 
will also require an analysis of the benefits and 
costs of regulating the issues of OSA diagnosis 
and treatment, an analysis not required for the 
issuance of guidance.  
 
This editorial provides a general overview of 
symptoms, risk factors, consequences, and 
treatments for OSA, as well as how the new 
legislation may impact OSA screening and 
treatment for CMV drivers and applicants. 
 
Obstructive Sleep Apnea (OSA), Traffic 
Accidents, and Treatment 
OSA involves interruptions of respiratory air 
flow and transient hypoxia during sleep, which 
disrupts and fragments the sleep pattern. People 
with untreated OSA may not be aware of their 
poor sleep quality, and this condition often leads 
to daytime sleepiness (USDOT, NHTSA, 2013). 
OSA is somewhat more common among males 
than among females, and typical OSA patients 
tend to be overweight with a large neck size, 
middle aged or older, and a history of loud 
snoring. Consistent with these OSA risk factors, 
CMV drivers generally male, have relatively 
high rates of obesity, and are older (Pack, et al., 
2002). In fact, OSA is far more prevalent among 
commercial motor vehicle (CMV) drivers (20%-
50%) as compared to the general driving 
population (3%-9%) (Pack, Dinges, & Maislin, 
2002). 
 
Undiagnosed sleep-disordered breathing, 
ranging from habitual snoring to repeated 
breathing interruptions, increases the likelihood 
of crashes in a dose-response manner (USDOT, 
NHTSA, 2013). OSA patients have a twofold to 
sevenfold increased risk of at-fault motor 
vehicle crashes (Young, Blustein, Finn, et al. 
1997). Furthermore CMV drivers with 
obstructive sleep apnea (OSA) have more 
accidents than CMV drivers without OSA 
(Tregear, Reston, Schoelles, & Phillips, 2009).  
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The good news is that OSA can be treated with a 
very high success rate. The most common 
therapy is a continuous positive airway pressure 
(CPAP) medical device that is used during sleep 
(George, 2001). CPAP equipment treats OSA by 
splinting open the upper airway during sleep 
with positive airway pressure applied through a 
facial or nasal mask via a hose connection. 
When the CPAP device is used correctly and 
every night, patients’ sleep can become more 
normalized in nearly all cases, which results in 
normal daytime functioning and alertness 
needed for safe driving. Full compliance with 
CPAP treatment procedures is approximately 
80% (George, 2001; Weaver et al., 2007).  
 
Current Screening Requirements for OSA 
among CMV Drivers 
Both the USDOT and the California Department 
of Motor Vehicles require that CMV drivers 
undergo a thorough medical examination every 
two years to screen for physical and mental 
health that can impair driving abilities 
(California Department of Motor Vehicles, 
2013). The only OSA screening information 
obtained from CMV driver applicants during the 
medical examination is a single self-report 
survey question which asks whether or not the 
respondent currently has an existing diagnosis of 
a sleep disorder, or experiences daytime fatigue 
(California Department of Motor Vehicles, 
2013). In other words, the California CMV 
driver medical examination contains no 
objective screening criteria for potential OSA. 
 
CMV driver applicants who screen positively for 
potential OSA become candidates for objective 
testing for OSA with diagnostic 
polysomnography (PSG).  This diagnostic test is 
costly, as it evaluates disordered breathing 
during sleep and allows for objective diagnosis 
of OSA and characterization of the severity of 
any OSA.   
 
Recommended Screening Requirements for 
OSA among CMV Drivers 
Due to the significant accident risk among CMV 
drivers with undetected and untreated OSA, 
criteria for objective screening of CMV drivers 
(e.g., neck circumference, blood pressure and 
body mass index, (BMI)) for possible OSA was 
established in 2006 by a task force of 
pulmonary, occupational, environmental, and 
sleep medicine experts (Hartenbaum et al., 
2006). The new, objective OSA screening 
criteria developed by the task force has high 
predictive validity for formal OSA diagnosis 
among CMV driver applicants (Talmage et al., 
2008) as well as CMV drivers (Parks et al., 
2009; Gurubhagavatula et al., 2004). Also other 
objective risk factors, such as hypertension, 
obesity, diabetes, has a higher predictive validity 
for formal OSA diagnosis among CMV drivers 
(Xie et al., 2011).  
 
Benefits and Barriers to OSA Treatment 
Since OSA is a very treatable medical condition, 
the recommendation to objectively screen CMV 
driver and CMV driver applicants for OSA 
appears eminently reasonable. The potential 
benefits of mandatory OSA screening for at-risk 
drivers are great. In a Department of 
Transportation report, fatigue was reported as a 
factor in 13% of large truck crashes (U.S. 
Department of Transportation, 2012). While not 
all driving fatigue is due to OSA, OSA screening 
would have the likelihood to reduce driver 
fatigue, and thus potentially reduce CMV 
accidents. Also, treating these drivers with 
undiagnosed OSA might have a benefit in 
ameliorating medical conditions associated with 
OSA, such as hypertension, diabetes, obesity 
and cardiovascular disease. 
 
Despite the apparent benefits of mandatory 
objective OSA screening, there are logistical and 
financial implications to establishing a 
mandatory OSA screening program for all CMV 
drivers. A significant percentage of CMV 
drivers, perhaps even the majority of them, 
would not pass the initial screening and would 
need follow-up PSG diagnostic testing, given the 
fact that the prevalence of CMV drivers with 
undetected OSA is 20%-50% (Pack et al., 2002). 
Employers would need to decide whether or not 
to pay for the cost of diagnostic testing and 
CPAP treatment for their current drivers who 
screen positive. Meanwhile these drivers will 
lose substantial income, as they will not be able 
to drive until they receive documentation that 
either rules out an OSA diagnosis or that he or 
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she has been successfully treated for OSA. 
Driver applicants who screen positive for OSA 
need to pay for diagnostic testing and treatment 
themselves; a lack of medical insurance is often 
a barrier for driver applicants to be fully 
evaluated and treated for OSA (Talmage, et al. 
2008; Parks, et al. 2009). Furthermore those 
drivers and driver applicants who pass the 
objective OSA screening will be expected to 
continuously meet the minimum BMI standards 
to renew their certification every two years. 
 
To Screen or Not to Screen? 
Because objective screening for OSA is not yet a 
law at a state or federal policy level, the CMV 
driver population contains drivers with 
undiagnosed and/or untreated OSA. We support 
mandatory OSA screening by medical examiners 
for all CMV drivers (relying upon the guidelines 
described by Hartenbaum et al., 2006 for 
establishment of regulations). Increasing health 
insurance coverage among the general 
population under the Affordable Care Act 
(ACA) may prove beneficial for those CMV 
driver applicants who require follow-up 
diagnostic testing and possible treatment for 
OSA. However at this time the extent to which 
such health insurance will cover OSA diagnostic 
testing and treatment is not completely known.  
 
Based upon what has been very recently 
accomplished in the aviation industry, 
overcoming barriers to mandatory screening of 
OSA among CMV drivers may be feasible. 
 
The Federal Aviation Administration (FAA) 
On November 20, 2013, the medical director of 
the Federal Aviation Administration (FAA) 
issued guidance regulations that objective OSA 
screening will be mandatory for all commercial 
pilots and air traffic controllers (U.S. 
Department of Transportation, Federal Aviation 
Administration, 2013). BMI and neck 
circumference thresholds are to be used for 
screening for OSA with further testing and 
treatment, as needed. In this memo delineating 
these regulatory changes, the FAA medical 
director indicated that OSA has significant 
safety implications ranging from excessive 
daytime sleepiness to personality disturbances, 
cognitive impairment and sudden cardiac death. 
The administrative details for the 
implementation of this FAA policy change are 
pending at this time. Unlike the FMCSA, the 
FAA is allowed to use guidance without 
undergoing a formal rule-making process. 
 
Conclusion 
The commercial trucking industry maintains that 
testing alone for obstructive sleep apnea of truck 
drivers could cost the industry nearly $1 billion 
(ATA, 2013). The financial burden for OSA 
testing and treatment will likely be borne by the 
self-employed CMV driver, as well as, by the 
commercial trucking industry. It is expected that 
the commercial trucking industry would take the 
position that the anticipated expense of OSA 
screening and treatment would create difficulties 
in recruiting and retaining employed CMV 
drivers and places an undue burden on 
independent, self-employed CMV drivers.     
 
It is likely that the federal rule-making process 
will slow the establishment of guidelines at the 
national level for OSA diagnosis and treatment 
among CMV drivers. Nonetheless, and despite 
the formidable hurdles of the federal rule-
making process, it is our opinion that federally 
mandated screening of CMV drivers for OSA 
with subsequent treatment as needed is 
necessary and should be implemented without 
delay as a national policy matter of public 
safety.  
 
© 2013 Californian Journal of Health Promotion. All rights reserved. 
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